Stay updated on Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial
Sign up to get notified when there's something new on the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page.
Latest updates to the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page
- Check4 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check11 days agoChange DetectedThe website has updated the intervention type information to reflect a verified status by the PETHEMA Foundation as of September 2022, while also noting a revision from v2.13.3 to v2.14.0.SummaryDifference3%
- Check18 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.3%
- Check48 days agoChange DetectedThe website has been updated from version 2.12.2 to 2.13.2, indicating a new release with potential improvements or features.SummaryDifference0.3%
- Check62 days agoChange DetectedThe website has removed a detailed section regarding data download options and fields related to clinical study information.SummaryDifference13%
- Check76 days agoChange DetectedThe website has been updated to version v2.12.2, introducing new download options for data in various formats and a comprehensive selection of study fields, while the 'Recruiting' status has been removed from the previous version.SummaryDifference16%
Stay in the know with updates to Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Low-Dose Cytarabine/Azacitidine+Venetoclax+Quizartinib in AML Clinical Trial page.